<DOC>
	<DOC>NCT01467921</DOC>
	<brief_summary>Oxaliplatin is a platinum analogue that has significant antitumor activity with better tolerability than cisplatin. The objective of the study is to evaluate the safety and activity of leucovorin and 5-fluorouracil and leucovorin and 5-fluorouracil plus oxaliplatin combination chemotherapy given as adjuvant therapy for curatively-resected, node-positive esophageal cancer.</brief_summary>
	<brief_title>Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Aged 20 years or older Histologically confirmed squamous cell carcinoma of esophagus Curatively (R0) resected, lymph node positive ECOG performance status of 0 or 1 Restoration of oral intake &gt;1500 kcal/d No prior chemotherapy except for neoadjuvant ones No prior radiotherapy within 1 month before registration Adequate marrow, hepatic, renal and cardiac functions Provision of a signed written informed consent Severe comorbid illness and/or active infections Prior treatment with oxaliplatin Pregnant or lactating women Active CNS metastases not controllable with radiotherapy or corticosteroids Known history of hypersensitivity to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>